Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
7.780 USD   -5.24%
02/02Allogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Technology
AQ
02/01Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
GL
02/01Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cellectis S.A. and Les Laboratoires Servier Sas and Institut De Recherches Internationales Servier Sas Notifies Allogene Their Disinvolvement in the Development of the CD19 Products and Purporting to Provide Allogene with the Ability to Elect to Obtain A License to the CD19 Products Outside of the United States

09/22/2022 | 04:32pm EST

Under the License, Development and Commercialization Agreement dated March 6, 2019, between Cellectis S.A. and Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier), as amended on March 4, 2020, Servier currently holds an exclusive worldwide license to develop and commercialize gene-edited allogeneic CAR T-cell products targeting CD19, including UCART19, ALLO-501 and ALLO-501A (collectively, “CD19 Products”). The exclusive rights for the development and commercialization of CD19 Products in the United States have been sublicensed by Servier to Allogene Therapeutics, Inc. On September 21, 2022, Allogene announced that it had received from Servier a notice pursuant to the Exclusive License and Collaboration Agreement between Allogene and Servier notifying Allogene that Servier was discontinuing its involvement in the development of the CD19 Products and purporting to provide Allogene with the ability to elect to obtain a license to the CD19 Products outside of the United States. Although the foregoing items may result in additional costs and expenses and could potentially result in delays in the development or commercialization of the CD19 Products, they do not expect these matters to have a material adverse impact on overall development program or long-term financial condition.


ę S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALLOGENE THERAPEUTICS, INC. -5.24% 7.78 Delayed Quote.30.52%
CELLECTIS S.A. -20.67% 2.38 Real-time Quote.50.98%
All news about ALLOGENE THERAPEUTICS, INC.
02/02Allogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Tec..
AQ
02/01Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade..
GL
02/01Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade..
GL
02/01Allogene Therapeutics, Inc. Presents Data on Dagger, a Next Generation AlloCAR T Platfo..
CI
01/25Allogene Therapeutics Says Preclinical Results Back DLL3 as Potential Treatment for Lun..
MT
01/25Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1..
AQ
01/25Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting..
GL
01/25Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting..
GL
01/25Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting..
CI
01/25North American Morning Briefing: Microsoft -2-
DJ
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,19 M - -
Net income 2022 -339 M - -
Net cash 2022 325 M - -
P/E ratio 2022 -3,28x
Yield 2022 -
Capitalization 1 122 M 1 122 M -
EV / Sales 2022 4 125x
EV / Sales 2023 281x
Nbr of Employees 356
Free-Float 57,2%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 7,78 $
Average target price 22,00 $
Spread / Average Target 183%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.30.52%1 184
REGENERON PHARMACEUTICALS, INC.5.06%80 230
VERTEX PHARMACEUTICALS9.87%77 978
WUXI APPTEC CO., LTD.15.80%41 417
BIONTECH SE-3.87%35 092
BEIGENE, LTD.15.96%26 559